Intermittent fasting two days versus one day per week, matched for total energy intake and expenditure, increases weight loss in overweight/obese men and women.
Fat mass
Fat-free mass
Hunger
Insulin-like growth factor -1 (IGF-1)
Intermittent fasting
Protein pacing
Weight loss
Journal
Nutrition journal
ISSN: 1475-2891
Titre abrégé: Nutr J
Pays: England
ID NLM: 101152213
Informations de publication
Date de publication:
04 06 2022
04 06 2022
Historique:
received:
19
01
2022
accepted:
26
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Intermittent fasting (IF), consisting of either a one-day (IF1) or two consecutive days (IF2) per week, is commonly used for optimal body weight loss. Our laboratory has previously shown an IF1 diet combined with 6d/week of protein pacing (P; 4-5 meals/day evenly spaced, ~ 30% protein/day) significantly enhances weight loss, body composition, and cardiometabolic health in obese men and women. Whether an IF1-P or IF2-P, matched for weekly energy intake (EI) and expenditure (EE), is superior for weight loss, body composition, and cardiometabolic health is unknown. This randomized control study directly compared an IF1-P (n = 10) versus an IF2-P (n = 10) diet on weight loss and body composition, cardiovascular (blood pressure and lipids), hormone, and hunger responses in 20 overweight men and women during a 4-week weight loss period. Participants received weekly dietary counseling and monitoring of compliance from a registered dietitian. All outcome variables were assessed pre (week 0) and post (week 5). Both groups significantly reduced body weight, waist circumference, percent body fat, fat mass, hunger, blood pressure, lipids, glucose, and increased percent fat-free mass (p < 0.05). However, IF2-P resulted in significantly greater reductions in body weight (-29%) and waist circumference (-38%) compared to IF1-P (p < 0.05), and showed a strong tendency for greater reductions in fat mass, glucose, and hunger levels (p < 0.10) despite similar weekly total EI (IF1-P, 9058 ± 692 vs. IF2-P, 8389 ± 438 kcals/week; p = 0.90), EE (~ 300 kcals/day; p = 0.79), and hormone responses (p > 0.10). These findings support short-term IF1-P and IF2-P to optimize weight loss and improve body composition, cardiometabolic health, and hunger management, with IF2-P providing enhanced benefits in overweight women and men. This trial was registered March 03, 2020 at www. gov as NCT04327141 .
Sections du résumé
BACKGROUND
Intermittent fasting (IF), consisting of either a one-day (IF1) or two consecutive days (IF2) per week, is commonly used for optimal body weight loss. Our laboratory has previously shown an IF1 diet combined with 6d/week of protein pacing (P; 4-5 meals/day evenly spaced, ~ 30% protein/day) significantly enhances weight loss, body composition, and cardiometabolic health in obese men and women. Whether an IF1-P or IF2-P, matched for weekly energy intake (EI) and expenditure (EE), is superior for weight loss, body composition, and cardiometabolic health is unknown.
METHODS
This randomized control study directly compared an IF1-P (n = 10) versus an IF2-P (n = 10) diet on weight loss and body composition, cardiovascular (blood pressure and lipids), hormone, and hunger responses in 20 overweight men and women during a 4-week weight loss period. Participants received weekly dietary counseling and monitoring of compliance from a registered dietitian. All outcome variables were assessed pre (week 0) and post (week 5).
RESULTS
Both groups significantly reduced body weight, waist circumference, percent body fat, fat mass, hunger, blood pressure, lipids, glucose, and increased percent fat-free mass (p < 0.05). However, IF2-P resulted in significantly greater reductions in body weight (-29%) and waist circumference (-38%) compared to IF1-P (p < 0.05), and showed a strong tendency for greater reductions in fat mass, glucose, and hunger levels (p < 0.10) despite similar weekly total EI (IF1-P, 9058 ± 692 vs. IF2-P, 8389 ± 438 kcals/week; p = 0.90), EE (~ 300 kcals/day; p = 0.79), and hormone responses (p > 0.10).
CONCLUSIONS
These findings support short-term IF1-P and IF2-P to optimize weight loss and improve body composition, cardiometabolic health, and hunger management, with IF2-P providing enhanced benefits in overweight women and men.
TRIAL REGISTRATION
This trial was registered March 03, 2020 at www.
CLINICALTRIALS
gov as NCT04327141 .
Identifiants
pubmed: 35658959
doi: 10.1186/s12937-022-00790-0
pii: 10.1186/s12937-022-00790-0
pmc: PMC9166203
doi:
Substances chimiques
Hormones
0
Lipids
0
Glucose
IY9XDZ35W2
Banques de données
ClinicalTrials.gov
['NCT04327141']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Informations de copyright
© 2022. The Author(s).
Références
Sci Transl Med. 2021 Jun 16;13(598):
pubmed: 34135111
Nutr Metab (Lond). 2012 Oct 31;9(1):98
pubmed: 23113919
Eur J Clin Nutr. 2020 Aug;74(8):1210-1220
pubmed: 32144378
Am J Clin Nutr. 2014 Jan;99(1):24-34
pubmed: 24196400
Annu Rev Nutr. 2021 Oct 11;41:333-361
pubmed: 34633860
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):973-996
pubmed: 32239651
J Transl Med. 2018 Dec 24;16(1):371
pubmed: 30583725
Cochrane Database Syst Rev. 2021 Jan 29;1:CD013496
pubmed: 33512717
Front Nutr. 2021 Mar 04;8:626432
pubmed: 33748175
Obesity (Silver Spring). 2019 Aug;27(8):1225-1238
pubmed: 31339001
Exerc Sport Sci Rev. 2020 Jan;48(1):4-10
pubmed: 31688298
Am J Physiol Endocrinol Metab. 2015 May 1;308(9):E734-43
pubmed: 25738784
Am J Epidemiol. 2012 Oct 1;176 Suppl 7:S44-54
pubmed: 23035144
Annu Rev Nutr. 2017 Aug 21;37:371-393
pubmed: 28715993
Br J Nutr. 2013 Oct;110(8):1534-47
pubmed: 23591120
JBI Database System Rev Implement Rep. 2018 Feb;16(2):507-547
pubmed: 29419624
J Appl Physiol (1985). 2014 Jul 1;117(1):1-10
pubmed: 24833780
Clin Nutr ESPEN. 2021 Feb;41:42-48
pubmed: 33487300
Exp Clin Endocrinol Diabetes. 2021 Mar;129(4):322-333
pubmed: 31860117
Int J Obes (Lond). 2011 Mar;35(3):448-56
pubmed: 20680017
Front Psychol. 2015 Feb 02;6:27
pubmed: 25698989
Am J Clin Nutr. 2021 Sep 13;:
pubmed: 34515299
Crit Rev Food Sci Nutr. 2021;61(17):2863-2875
pubmed: 32662279
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1690-1703
pubmed: 34668663
Nutr J. 2010 Sep 03;9:35
pubmed: 20815899
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):747-756
pubmed: 28844808
Obes Sci Pract. 2019 Sep 13;5(6):531-539
pubmed: 31890243
Nutr Rev. 2015 Oct;73(10):661-74
pubmed: 26374764
J Nutr. 2010 Apr;140(4):745-51
pubmed: 20164371
N Engl J Med. 2019 Dec 26;381(26):2541-2551
pubmed: 31881139
Free Radic Biol Med. 2007 Mar 1;42(5):665-74
pubmed: 17291990
Front Physiol. 2016 Aug 29;7:350
pubmed: 27621707
Obesity (Silver Spring). 2013 Jul;21(7):1357-66
pubmed: 23703835
Appetite. 2014 Oct;81:52-9
pubmed: 24911618
J Nutr. 2015 Feb;145(2):246-52
pubmed: 25644344
Nutrients. 2019 May 30;11(6):
pubmed: 31151228
Eur J Clin Nutr. 2021 Sep;75(9):1416-1417
pubmed: 34230626
Front Nutr. 2021 Oct 18;8:669325
pubmed: 34733872
Clin Nutr. 2016 Dec;35(6):1380-1385
pubmed: 27062219
Cell Metab. 2020 Mar 3;31(3):472-492
pubmed: 32130880
Nutrients. 2016 Jul 30;8(8):
pubmed: 27483317
Obesity (Silver Spring). 2018 Feb;26(2):254-268
pubmed: 29086496
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):698-706
pubmed: 29778565
Int J Obes (Lond). 2011 May;35(5):714-27
pubmed: 20921964
Am J Physiol Endocrinol Metab. 2014 Apr 15;306(8):E989-97
pubmed: 24595305
Am J Physiol Gastrointest Liver Physiol. 2021 May 1;320(5):G847-G863
pubmed: 33729005
Clin Nutr. 2020 Jun;39(6):1753-1763
pubmed: 31409509
Int J Environ Res Public Health. 2017 Jan 10;14(1):
pubmed: 28075418
J Int Soc Sports Nutr. 2013 Nov 01;10(1):50
pubmed: 24176020
Nutr J. 2012 Nov 21;11:98
pubmed: 23171320